An experimental levonorgestrel 20 mcg intrauterine device, the LNG20 IUD, is under development by Medicines360, a San Francisco-based nonprofit pharmaceutical company. The device's Phase 3 clinical trial began in 2009. It is projected to conclude in 2018.

• The company recently entered into a partnership with Actavis (formerly Watson Pharmaceuticals), a Parsippany, NJ-based pharmaceutical company, with an eye to allow Medicines360 to make the IUD available at a low price to U.S. public sector clinics.

• Should the device be approved by the Food and Drug Administration, the IUD could be launched in the United States as early as 2014.